Newest results of our R&D team at QPS Neuropharmacology validate severe and very early motor deficits in hA53Ttg mice, making this model well-suited for preclinical Parkinson’s disease (PD) research. PD belongs to the most devastating neurodegenerative diseases of the 21st century. The development of new drugs halting disease progression is therefore the main focus of …

To simplify dendritic spine analysis, our histology and IT team joined forces and developed a macro-based image analysis for rater-independent, unbiased, fast, and efficient automated dendritic spine quantification. Brain sections are stained by the Golgi-Cox method. For spine density analysis, Z-stack images are taken using 63x oil lens, and stacks are collapsed using Zeiss ZEN …

Newest results of our student’s FFG-funded PhD thesis at QPS Neuropharmacology in cooperation with Prof. Marcello Leopoldo from the University of Bari, Italy, confirms the value of Fmr1-knockout (KO) mice to model neurobehavioral deficits manifested in fragile X syndrome. Fragile X syndrome is the most commonly inherited form of intellectual disability and a monogenic cause …

In her FFG-funded PhD thesis at QPS Neuropharmacology in cooperation with Prof. Marcello Leopoldo from the University of Bari, Italy, Shirin Sharghi behaviorally characterized the BTBR T+ Itpr3tf/J mouse model of Autism Spectrum Disorders (ASD). BTBR T+ Itpr3tf/J mice were allocated to three different treatment groups of either LP-211 (a serotonergic compound), R-Baclofen (a GABAergic …

The glycogen storage disease type II (GSD II) is a rare, multisystemic disease with variable rates of disease progression that is also called Pompe disease. It is caused by alterations in the acid α-glucosidase (GAA) gene, resulting in reduced levels of this enzyme that in turn leads to a reduced degradation and thus accumulation of …